STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer

Neoplasia

Volumn 6, Issue 6, 2004, Pages 813-820

  Buess, Martin ^a   Terracciano, Luigi ^a   Reuter, Jurgen ^a   Ballabeni, Pierluigi ^b   Boulay, Jean Louis ^a   Laffer, Urban ^c   Metzger, Urs ^d   Herrmann, Richard ^a   Rochlitz, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c Spitalzentrum ^*  (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Colorectal cancer; Predictive; Prognostic markers; SMAD; STRAP; TGF

Indexed keywords

FLUOROURACIL; INHIBITOR PROTEIN; MITOMYCIN C; SERINE THREONINE RECEPTOR ASSOCIATED PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIPLOIDY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; TUMOR BIOPSY;

EID: 11144322863     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04307     Document Type: Article

References (29)

1. Wils J, O'Dwyer P, and Labianca R (2001). Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 12, 13-22.
2. Adlard JW, Richman SD, Seymour MT, and Quirke P (2002). Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3, 75-82.
3. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, and Danenberg PV (1997). Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15, 3223-3229.
4. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, et al. (2000). Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6, 1322-1327.
5. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, and Danenberg PV (1998). High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4, 2371-2376.
6. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, and Iacopetta B (2000). Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36, 2053-2060.
7. McKay JA, Lloret C, Murray GI, Johnston PG, Bicknell R, Ahmed FY, Cassidy J, and McLeod HL (2000). Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int J Oncol 17, 153-158.
8. Elsaleh H (2001). The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site. Gastroenterology 121, 230-231.
9. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB III and Hamilton SR (2001). Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344, 1196-1206.
10. Fearon ER and Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
11. Chung DC (2000). The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119, 854-865.
12. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338.
13. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353.
14. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, and Wakefield LM (1998). Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4, 802-807.
15. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al. (1999). Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59, 320-324.
16. Datta PK, Chytil A, Gorska AE, and Moses HL (1998). Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling. J Biol Chem 273, 34671-34674.
17. Datta PK and Moses HL (2000). STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol 20, 3157-3167.
18. Swiss Group for Clinical Cancer Research (SAKK) (1995). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345, 349-353.
19. Boulay JL, Reuter J, Ritschard R, Terracciano L, Herrmann R and Rochlitz C (1999). Gene dosage by quantitative real-time PCR. Biotechniques 27, 228-230, 232.
20. Therneau TaG PM (2000). In: Springer, PM (Ed.), Modeling Survival Data Springer, New York.
21. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18, 136-147.
22. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343, 905-914.
23. Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J, et al. (2001). Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 94, 623-629.
24. Henegariu O, Vance GH, Heiber D, Pera M, and Heerema NA (1998). Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band - specific painting probes. J Mol Med 76, 648-655.
25. Dong JT (2001). Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20, 173-193.
26. Matsuda S, Katsumata R, Okuda T, Yamamoto T, Miyazaki K, Senga T, Machida K, Thant AA, Nakatsugawa S, and Hamaguchi M (2000). Molecular cloning and characterization of human MAWD, a novel protein containing WD-40 repeats frequently overexpressed in breast cancer. Cancer Res 60, 13-17.
27. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, and Akhurst RJ (1996). TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542.
28. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, and Rochlitz C (2002). SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 87, 630-634.
29. 2-terminal kinase/activator protein-1 activation. Mol Pharmacol 64, 707-713.